Welcome to HL's reimagined News, Insights and Research experience. Find out more

Share research

CVS Group - trading in-line with expectations

CVS Group's first half trading has been in-line with expectations. Revenue rose 11.4% to £329.9mn, with like-for-like growth of 6%...

No recommendation - No news or research item is a personal recommendation to deal. All investments can fall as well as rise in value so you could get back less than you invest.

Prices delayed by at least 15 minutes

CVS Group's first half trading has been in-line with expectations. Revenue rose 11.4% to £329.9mn, with like-for-like growth of 6%. Cash profit (EBITDA) margins have held steady at around 19%.

There was a 4% increase in Healthy Pet Club membership to 500,000. CVS also acquired four more vet practices in Australia, taking the total to thirteen acquisitions.

The group is supporting the Competition and Markets Authority as their investigation into the vet sector continues. Findings are expected early this year.

The shares rose 1.4% following the announcement.

View the latest share price and how to deal

Our view

CVS is a one-stop shop for pet needs - the biggest business is its hundreds of vet clinics. But it also operates cremation services and an online pharmacy - Animed. There's a product or service available for pet owners at every stage of their pet's life.

The veterinary business is an attractive business to be in. People will spend on their furry companions, especially when it comes to health, no matter what's going on in the economy. The pandemic has seen pet ownership increase massively too. And not only this, but the way we treat our animals is playing into the hands of vets. So-called humanisation of animals means we're more willing to part with cash on check-ups and treatments for every sniffle and tummy upset. Half a million of us are signed up to the Healthy Pet Club subscription service, which makes custom even stickier.

Since listing in 2008, group earnings per share have grown steadily, fuelled by the acquisition of small independent vet practices.

Keeping acquisitions small limits the risk of each individual deal.

Acquisitions remain key, especially in the more fragmented Irish and Dutch markets. The group's also open to entering new geographies. The latest is a foray into Australia, which we think has good potential. CVS's financial position, when measured by debt levels, gives it scope to pounce on larger deals as they emerge, and its discipline at the negotiating table means that acquisitions are well placed to create shareholder value.

This operating model also helps to keep costs down. That helps to keep free cash flow pumping round the company's veins, which in turn underpins the group's ability to pay dividends. No dividend is guaranteed.

There are some things to keep an eye on. The company relies on a ready supply of highly skilled professionals. The entire vet industry is grappling with a vet shortage, and the associated retention and recruitment costs are onerous. This is a trend that may well get worse before it gets better.

The other elephant in the (waiting) room is the Competition and Market Authority's (CMA) decision to launch an investigation into the vet sector.

A crackdown on cross-selling of services between partner practices and a probe on pricing are unwelcome but not insurmountable. We remain hopeful that changes will need to be relatively minor, like making group branding more obvious (when CVS buys smaller clinics it currently tends to keep the original branding).

The CMA's findings, due early 2024, will be the main driver of sentiment in the short-term. Underneath the investigation, CVS Group is a high-quality business with growth potential, and we think the recent valuation dent has been overdone. But the risks of ups and downs are heightened.

CVS key facts

Please remember yields are variable and not a reliable indicator of future income. Keep in mind key figures shouldn't be looked at on their own - it's important to understand the big picture.

This article is original Hargreaves Lansdown content, published by Hargreaves Lansdown. It was correct as at the date of publication, and our views may have changed since then. Unless otherwise stated estimates, including prospective yields, are a consensus of analyst forecasts provided by Refinitiv. These estimates are not a reliable indicator of future performance. Yields are variable and not guaranteed. Investments rise and fall in value so investors could make a loss.

This article is not advice or a recommendation to buy, sell or hold any investment. No view is given on the present or future value or price of any investment, and investors should form their own view on any proposed investment. This article has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is considered a marketing communication. Non-independent research is not subject to FCA rules prohibiting dealing ahead of research, however HL has put controls in place (including dealing restrictions, physical and information barriers) to manage potential conflicts of interest presented by such dealing. Please see our full non-independent research disclosure for more information.

Latest from Share research
Weekly newsletter
Sign up for editors choice. The week's top investment stories, free in your inbox every Saturday.
Written by
Sophie Lund-Yates
Sophie Lund-Yates
Lead Equity Analyst

Sophie is a lead on our Equity Research team, providing research and regular articles on a selection of individual companies and wider sectors. Sophie's specialities are Retail, Fast Moving Consumer Goods (FMCG), Aerospace & Defence as well as a few of the big tech names including Facebook and Apple.

Our content review process
The aim of Hargreaves Lansdown's financial content review process is to ensure accuracy, clarity, and comprehensiveness of all published materials
Article history
Published: 25th January 2024